Webinar

Accelerated Tech Transfer From Development To Manufacturing For A COVID-19 Program

_92A0057-1-sized

The devastating effects wrought by the COVID-19 pandemic can only be mitigated by the rapid development and manufacture of vaccines and neutralizing antibodies. However, tech transfer remains a critical, time-consuming step on the path towards large-scale production of therapeutics in such times of crisis. Here we describe the acceleration of tech transfer to enable kickoff to vial thaw for antibody manufacture within three months for a clinical program and within five months for a process qualification campaign. We demonstrate various approaches to reduce the timeline from development to manufacturing at a 15kL scale. We also discuss the implications of this work towards enabling a rapid response to future pandemics, as well as introducing routine accelerated tech transfer to our site.

VIEW THE WEBINAR!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of BioProcess Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: